Integra Lifesciences Holdings Corp (NASDAQ:IART) Holdings Decreased by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its holdings in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 312,191 shares of the life sciences company’s stock after selling 4,964 shares during the period. Principal Financial Group Inc. owned about 0.37% of Integra Lifesciences worth $14,080,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Oregon Public Employees Retirement Fund lifted its position in shares of Integra Lifesciences by 4,410.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 1,226,245 shares in the last quarter. Enlightenment Research LLC purchased a new position in shares of Integra Lifesciences in the fourth quarter valued at approximately $32,000. Legacy Financial Advisors Inc. purchased a new position in shares of Integra Lifesciences in the fourth quarter valued at approximately $33,000. Fort L.P. purchased a new position in shares of Integra Lifesciences in the fourth quarter valued at approximately $34,000. Finally, Captrust Financial Advisors lifted its position in Integra Lifesciences by 43.6% during the fourth quarter. Captrust Financial Advisors now owns 2,330 shares of the life sciences company’s stock worth $105,000 after buying an additional 707 shares in the last quarter. 83.91% of the stock is currently owned by institutional investors.

In other Integra Lifesciences news, Director Rhonda Germany Ballintyn purchased 1,933 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was bought at an average cost of $56.08 per share, with a total value of $108,402.64. Following the acquisition, the director now directly owns 3,665 shares of the company’s stock, valued at $205,533.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lisa Evoli sold 1,291 shares of Integra Lifesciences stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $55.90, for a total value of $72,166.90. Following the sale, the insider now directly owns 4,968 shares of the company’s stock, valued at $277,711.20. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.

IART traded up $1.16 on Friday, hitting $52.54. 418,614 shares of the company were exchanged, compared to its average volume of 500,505. Integra Lifesciences Holdings Corp has a twelve month low of $42.14 and a twelve month high of $67.50. The stock has a market capitalization of $4.38 billion, a price-to-earnings ratio of 21.71, a PEG ratio of 1.56 and a beta of 0.96. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.95 and a quick ratio of 1.88.

Integra Lifesciences (NASDAQ:IART) last released its earnings results on Wednesday, April 24th. The life sciences company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.04. Integra Lifesciences had a return on equity of 16.02% and a net margin of 4.13%. The firm had revenue of $359.69 million during the quarter, compared to analysts’ expectations of $361.12 million. During the same period in the previous year, the firm posted $0.58 EPS. Integra Lifesciences’s revenue for the quarter was up .7% on a year-over-year basis. On average, research analysts anticipate that Integra Lifesciences Holdings Corp will post 2.68 earnings per share for the current year.

A number of equities analysts recently commented on the company. Oppenheimer reiterated a “buy” rating on shares of Integra Lifesciences in a research report on Tuesday, March 19th. JMP Securities reiterated a “buy” rating and set a $62.00 price objective on shares of Integra Lifesciences in a research report on Wednesday, February 27th. Morgan Stanley set a $57.00 price objective on Integra Lifesciences and gave the stock a “hold” rating in a research report on Friday, February 22nd. BidaskClub downgraded Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Finally, Zacks Investment Research upgraded Integra Lifesciences from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Tuesday. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $59.33.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/27/principal-financial-group-inc-lowers-holdings-in-integra-lifesciences-holdings-corp-iart.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: Why are gap-down stocks important?

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.